Login to Your Account



Repligen Plans NDA for Imaging Agent on Positive Phase III Data

By Staff Reports


Tuesday, March 15, 2011
Repligen Corp. reported that its imaging agent RG1068, a synthetic human secretin, showed statistically significant improvements in detecting pancreatic disease via magnetic resonance imaging, and the Waltham, Mass.-based firm plans to meet with the FDA to discuss a new drug application filing.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription